Clinical Trial

PRAISE-IR Versus CIBMTR Controls

Name: PRAISE-IR Versus CIBMTR Controls — clinical trial record (NCT07717164)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.

Protocol Amendment History 1 change

critical Primary endpoint(s) modified 2026-07-29

Trial Details

NCT Number	NCT07717164
Lead Sponsor	Miltenyi Biomedicine GmbH
Conditions	ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
Enrollment	51 participants
Start Date	2026-07-31
Primary Completion	2026-09-20 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-28